Filtered By:
Procedure: Heart Transplant
Therapy: Dialysis

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 84 results found since Jan 2013.

Risk factors for heart transplant survival with greater than 5  h of donor heart ischemic time
ConclusionPreservation time  >5  h is associated with worse survival. This mortality risk is further amplified by preoperative dialysis and ECMO, ischemic cardiomyopathy etiology, and use of O blood type donor hearts.
Source: Journal of Cardiac Surgery - May 21, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Paul C. Tang, Ienglam Lei, Y. E. Chen, Zhong Wang, Gorav Ailawadi, Matthew A. Romano, Shachi Salvi, Keith D. Aaronson, Ming ‐Sing Si, Francis D. Pagani, Jonathan W. Haft Tags: ORIGINAL ARTICLE Source Type: research

Valuing health states of people with type  2 diabetes: Analyses of the nationwide representative linked databases
ConclusionsMajor vascular complications, connective tissue disease and depression are associated with considerably worse health ‐related quality of life. These health utility estimates can facilitate health economic evaluations to determine cost‐effective strategies for diabetes management.
Source: Journal of Diabetes Investigation - March 3, 2021 Category: Endocrinology Authors: Shihchen Kuo, Chun ‐Ting Yang, Hsuan‐Ying Chen, Huang‐Tz Ou Tags: Original Article Source Type: research

Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databases
ConclusionsMajor vascular complications, connective tissue disease, and depression are associated with considerably worse HRQoL. These health utility estimates can facilitate health economic evaluations to determine cost ‐effective strategies for diabetes management.
Source: Journal of Diabetes Investigation - February 4, 2021 Category: Endocrinology Authors: Shihchen Kuo, Chun ‐Ting Yang, Hsuan‐Ying Chen, Huang‐Tz Ou Tags: ORIGINAL ARTICLE Source Type: research

Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
ConclusionThe significant adverse renal and cardiovascular outcomes observed, particularly in the DAPA-CKD-like cohort, represent a substantial burden resulting in increased mortality, HCRU and costs, demonstrating the need for additional treatment options.
Source: Advances in Therapy - January 20, 2021 Category: Drugs & Pharmacology Source Type: research

A mortality risk score for heart transplants after contemporary ventricular assist device bridging
ConclusionsAmong patients bridged to OHT with newer generation centrifugal LVADs, older age, increasing bilirubin, longer ischemic time, and pre ‐OHT dialysis independently predicted post‐transplant mortality. The composite risk score based on these factors may assist in patient selection and prognostication in those supported with contemporary LVADs.
Source: Journal of Cardiac Surgery - December 7, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Lauren V. Huckaby, Laura M. Seese, Gavin Hickey, Ibrahim Sultan, Arman Kilic Tags: ORIGINAL ARTICLE Source Type: research

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type  2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
ConclusionModel results suggest that adding canagliflozin 100  mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England.Trial RegistrationClinicalTrials.gov identifier, NCT02065791.
Source: Diabetes Therapy - December 2, 2020 Category: Endocrinology Source Type: research

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Outcome of CentriMag ™ extracorporeal mechanical circulatory support use in critical cardiogenic shock (INTERMACS 1) patients
ConclusionOur results demonstrate an excellent outcome with the use of the CentriMag ™ device in this seriously ill population. Despite requiring multiple procedures, over 58% of patients were discharged from hospital with 5-year survival of 46%.
Source: Indian Journal of Thoracic and Cardiovascular Surgery - September 29, 2020 Category: Cardiovascular & Thoracic Surgery Source Type: research

Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data
ConclusionCREDEM-DKD is an important new tool in the evaluation of treatment interventions in the DKD population.Trial RegistrationClinicalTrials.gov identifier, NCT02065791.
Source: Diabetes Therapy - September 14, 2020 Category: Endocrinology Source Type: research

Prognostic significance of right ventricular hypertrophy and systolic function in Anderson –Fabry disease
ConclusionsRVH and RV systolic function show significant association with clinical events in AFD, but only proteinuria and left ventricular mass index emerged as independent predictors of outcome. Our findings suggest that RV involvement does not influence prognosis in AFD and confirm that renal involvement and left ventricular hypertrophy are the main determinant of major cardiac and non ‐cardiac events.
Source: ESC Heart Failure - May 19, 2020 Category: Cardiology Authors: Francesca Graziani, Rosa Lillo, Elena Panaioli, Maurizio Pieroni, Antonia Camporeale, Elena Verrecchia, Ludovico Luca Sicignano, Raffaele Manna, Antonella Lombardo, Gaetano Antonio Lanza, Filippo Crea Tags: Original Research Article Source Type: research

Unusual Symptoms of Coronavirus: What We Know So Far
While most people are familiar with the hallmark symptoms of COVID-19 by now—cough, fever, muscle aches, headaches and difficulty breathing—a new crop of medical conditions are emerging from the more than 4 million confirmed cases of the disease around the world. These include skin rashes, diarrhea, kidney abnormalities and potentially life-threatening blood clots. It’s not unusual for viruses to directly infect and affect different tissues and organs in the body, but it is a bit unusual for a primarily respiratory virus like SARS-CoV-2, which is responsible for COVID-19, to have such a wide-ranging reach...
Source: TIME: Health - May 19, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Heart transplants from donors with hepatitis C may be safe and could help decrease organ shortage
(American Heart Association) One-year survival was 90% for adults with severe heart failure who received a heart transplant from a donor with hepatitis C, which was nearly identical to those who received a heart from donors who did not have hepatitis C (91%). Rates of organ rejection, stroke and kidney dialysis were similar between the two groups. More research is needed to assess longer-term results, however, increased use of hearts from donors with hepatitis C could help overcome the national shortage of donor organs.
Source: EurekAlert! - Medicine and Health - January 8, 2020 Category: International Medicine & Public Health Source Type: news

Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study
ConclusionsHigher MPO level was associated with increased risk for CKD progression, but not with CVD and death in patients with CKD from CRIC. Whether therapies aimed at reducing MPO activity can result in improved clinical outcomes is yet to be determined.
Source: American Journal of Kidney Diseases - December 20, 2019 Category: Urology & Nephrology Source Type: research